Roberto Leon-Ferre (@rleonferre) 's Twitter Profile
Roberto Leon-Ferre

@rleonferre

Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano 🇪🇨

ID: 115073699

calendar_today17-02-2010 14:41:51

998 Tweet

1,1K Takipçi

790 Takip Edilen

Mayo Clinic Comprehensive Cancer Center (@mayocancercare) 's Twitter Profile Photo

.Mayo Clinic oncologist Dr. Karthik Giridhar talks with OncLive.com about findings from an exploratory analysis of the phase 1 EMBER trial for patients with advanced or metastatic #BreastCancer or #EndometrialCancer. #ESMO24 bit.ly/3zhQQt1

.<a href="/MayoClinic/">Mayo Clinic</a> oncologist Dr. Karthik Giridhar talks with <a href="/OncLive/">OncLive.com</a> about findings from an exploratory analysis of the phase 1 EMBER trial for patients with advanced or metastatic #BreastCancer or #EndometrialCancer. #ESMO24 bit.ly/3zhQQt1
Conquer Cancer, the ASCO Foundation (@conquercancerfd) 's Twitter Profile Photo

Applications for Conquer Cancer research grants and awards are now open! Funding is available for researchers at every career stage. Learn more and apply now! brnw.ch/21wL4uc ASCO #OncAlert #ConquerCancer

Andrew Takchi (@andrewtakchimd) 's Twitter Profile Photo

🚨 Our study in Frontiers - Oncology reveals a novel positive feedback loop between AURKA and PD-L1 in triple negative breast cancer. Dual blockade shows promise in inhibiting tumor growth and metastasis. frontiersin.org/journals/oncol… #CancerResearch #TNBC #Oncology

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Thanks to the The ASCO Post for featuring our JCO publication of the #ATEMPT 5y update! With <1% risk of distant recurrence at 5 years & improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC. ascopost.com/news/july-2024…

Thanks to the <a href="/ASCOPost/">The ASCO Post</a> for featuring our JCO publication of the #ATEMPT 5y update! With &lt;1% risk of distant recurrence at 5 years &amp; improved quality of life over chemo, adjuvant T-DM1 should be considered as a valid alternative to TH for stage I HER2+ BC. ascopost.com/news/july-2024…
OncoDaily (@oncodaily) 's Twitter Profile Photo

Optimal Anastrozole Dose for Estrogen Suppression in Postmenopausal Breast Cancer oncodaily.com/108556.html Tufia Haddad, Brenda Ernst, MD, Zeruesenay Desta, Roberto Leon-Ferre, Kathryn Ruddy, Matthew Goetz #Oncology #Cancer #ResearchPapers #BreastCancer #BCSM #Postmenopausal

ASCO (@asco) 's Twitter Profile Photo

👏 Join us in congratulating our members who earned the Fellows of ASCO (FASCO) distinction this quarter! We're grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wLvZf

👏 Join us in congratulating our members who earned the Fellows of ASCO (FASCO) distinction this quarter! We're grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wLvZf
Dionisia Quiroga, DO, PhD (@quirogad) 's Twitter Profile Photo

👩🏽‍🏫 my ASCO TECAG colleagues and I put together this workbook on the what, when, why, and how of mentoring for #hemeonc trainees and early career physicians Check it out 👀 and let us know how you’ve been able to form effective mentoring relationships! ASCO Hem-Onc Fellows Network

Pablo Mando (@pablomando) 's Twitter Profile Photo

📣Linda oportunidad para todos los oncólogos jovenes de LATAM para conocer la experiencia de 2 grandes especialistas sobre investigación y ensayos clínicos en escenarios con recursos limitados. Los esperamos!!! ESMO - Eur. Oncology #ESMOYOC

Malke Asaad (@malkeasaad) 's Twitter Profile Photo

HUGE 💣 news for IMGs! The American Board of internal medicine is considering a pathway that allows American BOARD certification with just a fellowship in the U.S. without U.S. residency!

HUGE 💣 news for IMGs! The American Board of internal medicine is considering a pathway that allows American BOARD certification with just a fellowship in the U.S. without U.S. residency!
Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm